ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional Results available

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT04158739

Public ClinicalTrials.gov record NCT04158739. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Study identification

NCT ID
NCT04158739
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Children's Oncology Group
Network
Enrollment
16 participants

Conditions and interventions

Interventions

  • Cytarabine Drug
  • Flotetuzumab Biological

Drug · Biological

Eligibility (public fields only)

Age range
Up to 20 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 21, 2020
Primary completion
Sep 29, 2022
Completion
Mar 30, 2026
Last update posted
Jan 22, 2026

2020 – 2026

United States locations

U.S. sites
19
U.S. states
16
U.S. cities
19
Facility City State ZIP Site status
Children's Hospital of Alabama Birmingham Alabama 35233
Children's Hospital Los Angeles Los Angeles California 90027
Children's Hospital of Orange County Orange California 92868
UCSF Medical Center-Mission Bay San Francisco California 94158
Children's Hospital Colorado Aurora Colorado 80045
Children's National Medical Center Washington D.C. District of Columbia 20010
Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta Georgia 30329
Lurie Children's Hospital-Chicago Chicago Illinois 60611
Riley Hospital for Children Indianapolis Indiana 46202
C S Mott Children's Hospital Ann Arbor Michigan 48109
University of Minnesota/Masonic Cancer Center Minneapolis Minnesota 55455
Washington University School of Medicine St Louis Missouri 63110
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224
Saint Jude Children's Research Hospital Memphis Tennessee 38105
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston Texas 77030
Seattle Children's Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04158739, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 22, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04158739 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →